Singapore, 28 July 2025-RafflesMedicalGroup (the Group) posted a revenue of S$378.4 million, and Profit After Tax of S$32.5 million. Profit after tax and minority interests (PATMI) rose to S$32.1 million, supported by stable operational performance across core segments. These changes reflect a 3.5% increase in revenue and a 4.8% improvement in PATMI year-on-year.

While the Healthcare Services division recorded a modest 0.6% increase in revenue to S$142.2 million and reported a profit of S$24.9 million, the Group’s Hospital Services division remainedstrong and profitable, registering a revenue of S$174.0 million and profit of S$17.7 million.

RafflesChinaHealthcare＇s revenue increased marginally from CNY162.9 (S$29.9) million in 1H 2024 to CNY163.6 (S$30.5) million in 1H 2025. The RafflesHospital brand has gained wider recognition and trust among patients in China, reinforcing its position as a trusted quality healthcare provider. Cost-saving measures that were put in place earlier have proven effective in helping to reduce initial losses.

RafflesHealthinsurance＇s(RHI) revenue grew by 10.0% to S$94.9 million and incurred an operating loss of S$3.1 million as compared to a loss of S$6.4 million in the previous year. RHI's loss reduced by 51.7% compared to 1H 2024, due to more rigorous claims adjudication and prudent expense management.

The Group generated S$56.6 million in operating cash flow during the period. Dividends totalling S$46.3 million were distributed to shareholders following RMG’s Annual General Meeting in April 2025. Reflecting its disciplined capital management and strong operating cash flow, the Group had revised its dividend policy in February this year to distribute at least 50% of sustainable earnings annually and to buy back up to 100 million ordinary shares over the next two years.

The Group’s balance sheet remained strong with S$334.2 million in cash and cash equivalents as of 30 June 2025.

Business Updates

• Forging in-depth partnerships to provide seamless and high-quality cross-border healthcare experiences to more patients.

In March and June this year, RafflesMedicalGroup signed two strategic partnerships with Shanghai＇s Renji Hospital and Chongqing＇s First Affiliated Hospital respectively to establish a new model for medical cooperation between Singapore and China. These partnerships are deeply aligned with the Group＇s mission and core values, as well as with China＇s “Healthy China 2030” strategy and the call to strengthen international medical cooperation. By integrating international standards with local expertise, the Group seeks to drive medical innovation and raise the overall quality of care as it remains committed to delivering high-quality, patient-centred healthcare across Asia.

• Innovating care delivery while enhancing operational efficiency

As Singapore＇s population ages and life expectancy increases, RMG remains committed to innovation and forward-thinking care, while proactively adapting to emerging health trends to stay resilient and relevant in a rapidly evolving healthcare landscape. At the same time, the Group remains focused on enhancing operational efficiency by optimising resource utilisation, streamlining care delivery processes, and driving specialty-driven services across its facilities.

Based on current conditions and barring unforeseen circumstances, the Board expects the Group to remain profitable in FY2025.

“We are constantly innovating to stay relevant and provide the best care to meet our patients’ evolving health needs. Through strategic partnerships and collaboration with leading healthcare experts, we are well-positioned to extend the Raffles brand of care to more people both locally and across the region,” said Dr Loo Choon Yong, Executive Chairman, Raffles Medical Group.